Page 780 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

758 PART IV Specific Malignancies in the Small Animal Patient

248. Cotter SMGM: Treatment of lymphoma and leukemia with cyclo- 269. Morges MA, Burton JH, Saba CF, et al.: Phase II evaluation of
phosphamide, vincristine and prednisone: I. Treatment of dog, VDC-1101 in canine cutaneous T-cell lymphoma, J Vet Intern Med
J Am Anim Hosp Assoc 19:159–165, 1983. 28:1569–1574, 2014.
VetBooks.ir 249. Boyce KLKB: Treatment of canine lymphoma with COPLA/LVP, 270. Saba CF, Vickery KR, Clifford CA, et al.: Rabacfosadine for
J Am Anim Hosp Assoc 36:395–403, 2000.
relapsed canine B-cell lymphoma: Efficacy and adverse event pro-
250. Postorino NC, Susaneck SJ, Withrow SJ, et al.: Single agent ther-
files of 2 different doses, Vet Comp Oncol 16:E76–E82, 2018.
apy with adriamycin for canine lymphosarcoma, J Am Anim Hosp 271. Jeffreys AB, Knapp DW, Carlton WW, et al.: Influence of aspara-
Assoc 25:221–225, 1989. ginase on a combination chemotherapy protocol for canine multi-
251. Stone MSGM, Cotter SM, et al.: Comparison of two protocols for centric lymphoma, J Am Anim Hosp Assoc 41:221–226, 2005.
induction of remission in dogs with lymphoma, J Am Anim Hosp 272. MacDonald VS, Thamm DH, Kurzman ID, et al.: Does L-asparagi-
Assoc 27:315–321, 1991. nase influence efficacy or toxicity when added to a standard CHOP
252. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard protocol for dogs with lymphoma? J Vet Intern Med 19:732–736,
regimen (CHOP) with three intensive chemotherapy regimens for 2005.
advanced non-Hodgkin’s lymphoma, N Engl J Med 328:1002– 273. Carter RF, Harris CK, Withrow SJ, et al.: Chemotherapy of canine
1006, 1993. lymphoma with histopathologial correlation: doxorubicin alone
253. Vail DM, Michels GM, Khanna C, et al.: Response evaluation cri- compared to COP as first treatment regimen, J Am Anim Hosp Assoc
teria for peripheral nodal lymphoma in dogs (v1.0)—a Veterinary 23:587–596, 1987.
Cooperative Oncology Group (VCOG) consensus document, Vet 274. Lori JC, Stein TJ, Thamm DH: Doxorubicin and cyclophospha-
Comp Oncol 8:28–37, 2010. mide for the treatment of canine lymphoma: a randomized, pla-
254. Tomiyasu H, Takahashi M, Fujino Y, et al.: Gastrointestinal and cebo-controlled study, Vet Comp Oncol 8:188–195, 2010.
hematologic adverse events after administration of vincristine, 275. Sauerbrey ML, Mullins MN, Bannink EO, et al.: Lomustine and
cyclophosphamide, and doxorubicin in dogs with lymphoma that prednisone as a first-line treatment for dogs with multicentric lym-
underwent a combination multidrug chemotherapy protocol, J Vet phoma: 17 cases (2004-2005), J Am Vet Med Assoc 230:1866–1869,
Med Sci 72:1391–1397, 2010. 2007.
255. Vail DM: Cytotoxic chemotherapy agents, Clin Brief 8:18–22, 276. Khanna C, Lund EM, Redic KA, et al.: Randomized controlled
2010. trial of doxorubicin versus dactinomycin in a multiagent protocol
256. Mellanby RJ, Herrtage ME, Dobson JM: Owners’ assessments of for treatment of dogs with malignant lymphoma, J Am Vet Med
their dog’s quality of life during palliative chemotherapy for lym- Assoc 213:985–990, 1998.
phoma, J Small Anim Pract 44:100–103, 2003. 277. Marconato L, Stefanello D, Valenti P, et al.: Predictors of long-term
257. Bronden LB, Rutteman GR, Flagstad A, et al.: Study of dog and survival in dogs with high-grade multicentric lymphoma, J Am Vet
cat owners’ perceptions of medical treatment for cancer, Vet Rec Med Assoc 238:480–485, 2011.
152:77–80, 2003. 278. Price GS, Page RL, Fischer BM, et al.: Efficacy and toxicity of
258. Lautscham EM, Kessler M, Ernst T, et al.: Comparison of a doxorubicin/cyclophosphamide maintenance therapy in dogs with
CHOP-LAsp-based protocol with and without maintenance for multicentric lymphosarcoma, J Vet Intern Med 5:259–262, 1991.
canine multicentric lymphoma, Vet Rec 180:303, 2017. 279. Fournier Q, Serra JC, Handel I, et al.: Impact of pretreatment neu-
259. Moore AS, Cotter SM, Rand WM, et al.: Evaluation of a discon- trophil count on chemotherapy administration and toxicity in dogs
tinuous treatment protocol (VELCAP-S) for canine lymphoma, with lymphoma treated with CHOP chemotherapy, J Vet Intern
J Vet Intern Med 15:348–354, 2001. Med 32:384–393, 2018.
260. Piek CJ, Rutteman GR, Teske E: Evaluation of the results of a 280. Mealey KL, Fidel J, Gay JM, et al.: ABCB1-1Delta polymorphism
L-asparaginase-based continuous chemotherapy protocol versus a can predict hematologic toxicity in dogs treated with vincristine,
short doxorubicin-based induction chemotherapy protocol in dogs J Vet Intern Med 22:996–1000, 2008.
with malignant lymphoma, Vet Q 21:44–49, 1999. 281. Beaver LM, Strottner G, Klein MK: Response rate after adminis-
261. Rassnick KM, McEntee MC, Erb HN, et al.: Comparison of 3 tration of a single dose of doxorubicin in dogs with B-cell or T-cell
protocols for treatment after induction of remission in dogs with lymphoma: 41 cases (2006-2008), J Am Vet Med Assoc 237:1052–
lymphoma, J Vet Intern Med 21:1364–1373, 2007. 1055, 2010.
262. Zenker I, Meichner K, Steinle K, et al.: Thirteen-week dose-intensi- 282. Dobson JM, Blackwood LB, McInnes EF, et al.: Prognostic vari-
fying simultaneous combination chemotherapy protocol for malig- ables in canine multicentric lymphosarcoma, J Small Anim Pract
nant lymphoma in dogs, Vet Rec 167:744–748, 2010. 42:377–384, 2001.
263. Ruslander D, Moore AS, Gliatto JM, et al.: Cytosine arabinoside as 283. Rebhun RB, Kent MS, Borrofka SA, et al.: CHOP chemotherapy
a single agent for the induction of remission in canine lymphoma, for the treatment of canine multicentric T-cell lymphoma, Vet
J Vet Intern Med 8:299–301, 1994. Comp Oncol 9:38–44, 2011.
264. Rassnick KM, Frimberger AE, Wood CA, et al.: Evaluation of ifos- 284. Brown PM, Tzannes S, Nguyen S, et al.: LOPP chemotherapy as a
famide for treatment of various canine neoplasms, J Vet Intern Med first-line treatment for dogs with T-cell lymphoma, Vet Comp Oncol
14:271–276, 2000. 16:108–113, 2018.
265. Smith AA, Lejeune A, Kow K, et al.: Clinical response and adverse 285. Goodman IH, Moore AS, Frimberger AE: Treatment of canine
event profile of bleomycin chemotherapy for canine multicentric non-indolent T cell lymphoma using the VELCAP-TSC protocol:
lymphoma, J Am Anim Hosp Assoc 53:128–134, 2017. a retrospective evaluation of 70 dogs (2003-2013), Vet J 211:39–
266. Turner AI, Hahn KA, Rusk A, et al.: Single agent gemcitabine che- 44, 2016.
motherapy in dogs with spontaneously occurring lymphoma, J Vet 286. Brodsky EM, Maudlin GN, Lachowicz JL, et al.: Asparaginase
Intern Med 20:1384–1388, 2006. and MOPP treatment of dogs with lymphoma, J Vet Intern Med
267. Reiser H, Wang J, Chong L, et al.: GS-9219—a novel acyclic 23:578–584, 2009.
nucleotide analogue with potent antineoplastic activity in dogs 287. Gentilini F, Turba ME, Forni M: Retrospective monitoring of
with spontaneous non-Hodgkin’s lymphoma, Clin Cancer Res minimal residual disease using hairpin-shaped clone specific prim-
14:2824–2832, 2008. ers in B-cell lymphoma affected dogs, Vet Immunol Immunopathol
268. Thamm DH, Vail DM, Kurzman ID, et al.: GS-9219/VDC- 153:279–288, 2013.
1101—a prodrug of the acyclic nucleotide PMEG has antitumor 288. Sato M, Yamazaki J, Goto-Koshino Y, et al.: Minimal residual dis-
activity in spontaneous canine multiple myeloma, BMC Vet Res ease in canine lymphoma: an objective marker to assess tumour cell
10(30), 2014. burden in remission, Vet J 215:38–42, 2016.